Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDanshensuCat.No.:HY-N1913CASNo.:76822-21-4Synonyms:DanshensuanA;SalvianicacidA分?式:C?H??O?分?量:198.17作?靶點(diǎn):Keap1-Nrf2;Autophagy;Apoptosis作?通路:NF-κB;Autophagy;Apoptosis儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:5mg/mL(25.23mM;Needultrasonic)DMSO:1mg/mL(5.05mM;ultrasonicandwarmingandheatto80°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM5.0462mL25.2309mL50.4617mL5mM1.0092mL5.0462mL10.0923mL10mM0.5046mL2.5231mL5.0462mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請(qǐng)依序添加每種溶劑：PBSSolubility:10mg/mL(50.46mM);Clearsolution;Needultrasonicandheatto60°CBIOLOGICALACTIVITY?物活性Danshensu丹參的有效成分，能夠激活Nrf2信號(hào)通路，保護(hù)??管。體外研究Danshensu(DSS)significantlydecreasesthelevelofthemarkerenzymes(creatinekinaseandlactatedehydrogenase)fromthecoronaryeffluentsandmyocardialinfarctionsize.ThiscouldmarkedlycontributetotherecoveryofcardiacfunctionafterI/Rinjury.DSSalsohasROSscavengingactivityandboostsendogenousantioxidantssuchasSOD,CAT,MDA,GSH-PXandHO-1activitiesbyactivatingnuclearfactorerythroid-2-relatedfactor2(Nrf2)signalingpathwaywhichismediatedbyAktandERK1/2inwesternblotanalysis[2].體內(nèi)研究AcutetreatmentwithasingledoseofdanshensuinratswithnormaltHcydoesnotchangeplasmatHcy.Incontrast,danshensusignificantlylowerstHcyinratswithelevatedtHcy.TherelativelyhighercysteineandglutathionelevelsaftertreatmentwithdanshensuindicatesthatitstHcy-loweringeffectisviaincreasedactivityofthetrans-sulphurationpathway[1].PROTOCOLAnimalAllchemicalsaredissolvedinsaline,exceptfortolcaponewhichisdissolvedinsalinecontaining20%(v/v)Administration[1]PEG200.Duringexperiments,ratsarefastedovernightandrandomLyassignedintodifferentgroups.About200μLbloodistakenfromorbitalsinusalternativelyafterethyletheranaesthesia,andthentheeyeisquicklysterilizedwithalcoholandpressedwithcotton.Bloodsamplesareimmediatelycollectedintoapolypropylenetubecontainingheparin-Naandcentrifugedat5000gat5°Cfor3min.Preparedplasmasamplesarekeptat?20°Candanalysedwithin48h.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.REFERENCES[1].YGCao,etal.Beneficialeffectsofdanshensu,anactivecomponentofSalviamiltiorrhiza,onhomocysteinemetabolismviathetrans-sulphurationpathwayinrats.BrJPharmacol.2009Jun;157(3):482–490.[2].YuJ,etal.DanshensuprotectsisolatedheartagainstischemiareperfusioninjurythroughactivationofAkt/ERK1/2/Nrf2signaling.IntJClinExpMed.2015Sep15;8(9):14793-804.McePdfHeightCaution:Producthasnotbeenfullyvalid